Kenneth Berlin - Rosetta Genomics CEO and Pres
CEO
Mr. Kenneth A. Berlin is no longer President, Chief Executive Officer of the company effective April 18, 2018. He was later appointed by our shareholders in December 2009 as a member of our board of directors, and resigned as a director in March 2011. Prior to joining us, Mr. Berlin, served as Worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex, LLC, a Johnson Johnson company. Under his leadership the organization grew to over 100 employees, and he spearheaded the launch of three cancer diagnostic products, the acquisition of its cellular diagnostics partner, and delivered significant growth in sales as Veridex transitioned from a research and development entity to a commercial provider of oncology diagnostic products and services. During Mr. Berlins tenure, Veridex received numerous awards including recognition from the Cleveland Clinic and Prix Galien for the use of its innovative CellSearch technology in the fight against cancer. Mr. Berlin joined Johnson Johnson in 1994 and served as corporate counsel for six years. He then held positions of increasing responsibility within Johnson Johnson and a number of its subsidiary companies. From 2001 until 2004, he served as Vice President, licensing and new business development in the pharmaceuticals group, and from 2004 until 2007 was Worldwide Vice President, franchise development, OrthoClinical Diagnostics
| Age | 50 |
| Phone | 972 73 222 0700 |
| Web | http://www.rosettagx.com |
Rosetta Genomics Management Efficiency
The company has return on total asset (ROA) of (60.19) % which means that it has lost $60.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (137.95) %, meaning that it created substantial loss on money invested by shareholders. Rosetta Genomics' management efficiency ratios could be used to measure how well Rosetta Genomics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics has a current ratio of 2.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Rosetta Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Rosetta Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rosetta Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rosetta to invest in growth at high rates of return. When we think about Rosetta Genomics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 5 records | CEO Age | ||
| David Auld | DR Horton | 68 | |
| Omar Abbosh | Pearson PLC ADR | 58 | |
| John Fallon | Pearson PLC ADR | 57 | |
| Andy Bird | Pearson PLC ADR | 57 | |
| Kimberly McWaters | Universal Technical Institute | 56 | |
Management Performance
| Return On Equity | -137.95 | |||
| Return On Asset | -60.19 |
Rosetta Genomics Leadership Team
Elected by the shareholders, the Rosetta Genomics' board of directors comprises two types of representatives: Rosetta Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rosetta. The board's role is to monitor Rosetta Genomics' management team and ensure that shareholders' interests are well served. Rosetta Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rosetta Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Sidransky, Independent Director | ||
| Kenneth Berlin, CEO and Pres | ||
| Anne Fields, IR Contact Officer | ||
| Joshua Rosensweig, Director | ||
| Dganit Bar, Chief Scientific Officer | ||
| Brian Markison, Chairman, Observer To Board of Directors and Member of Nominating and Corporate Governance Committee | ||
| Douglas Sites, Executive Vice President - Sales and Marketing | ||
| Tal YaronEldar, Independent Director | ||
| Eti Meiri, Vice President - Research | ||
| Robert Wassman, Chief Medical Officer | ||
| Oded Biran, General Counsel | ||
| Roy Davis, Director | ||
| Yitzhak Peterburg, Director | ||
| Kevin Watson, Director, Reimbursement-Managed Care | ||
| Ron Kalfus, CFO | ||
| Gerald Dogon, External Independent Director | ||
| Tali YaronEldar, External Independent Director |
Rosetta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rosetta Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -137.95 | |||
| Return On Asset | -60.19 | |||
| Operating Margin | (370.55) % | |||
| Current Valuation | 2.09 M | |||
| Shares Outstanding | 5.93 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 14.42 % | |||
| Number Of Shares Shorted | 310.26 K | |||
| Price To Earning | (0.09) X | |||
| Price To Book | 1.01 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Rosetta Stock
If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |